A frontline worker reacrs as she receives a shot of AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)
The Associated Press
KAMPALA, Uganda (AP) - The head of the Africa Centers for Disease Control and Prevention warned against a 'œvaccine war'ť among nations amid renewed fears vaccine shipments to the continent face delays.
John Nkengasong said in a briefing Thursday that he 'œtruly feels helpless that this situation is going to significantly impact our ability to fight this virus," referring to reports that the Serum Institute of India is suspending major exports of the AstraZeneca COVID-19 vaccine in order to meet rising demand at home.
'œWithout ramping (up) access to vaccines we will be challenged, continue to be challenged. Lives will be lost,'ť Dr. Nkengasong said, noting that he remains hopeful "the power of humanity will prevail.'ť
He added: 'œThere is absolutely no need, absolutely no need for us as humanity to go into a vaccine war to fight this pandemic. We will all be losers.'ť
The Serum Institute of India produces the AstraZeneca shots being shipped to Africa through the international COVAX initiative to ensure vaccine access for low- and middle-income countries. At least 28 of Africa's 54 countries have received over 16 million doses via COVAX as of Thursday.
Vaccine shipments through COVAX continue to arrive across Africa. South Sudan, for example, on Thursday received its first batch of 132,000 doses of the AstraZeneca vaccine in what WHO called 'œa giant step'ť toward equitable distribution of COVID-19 vaccines worldwide.
But COVAX has been facing delays related to the limited global supply of vaccine doses as well as logistical issues. That's why some countries such as South Africa, the hardest-hit African nation, are also pursuing COVID-19 vaccines via bilateral deals and through the African Union's bulk-purchasing program.
At least 10 African countries are yet to receive vaccines, according to the World Health Organization's regional office for Africa. Those countries include Tanzania, Burundi, Eritrea, Cameroon, and Chad.
The continent has "has received limited doses and much later than the rest of the world,'ť Dr. Richard Mihigo, a program coordinator in charge of immunization and vaccine development with WHO's Africa office, said in a briefing Thursday.
'œWe are concerned that while COVAX vaccinations have enabled many African countries to roll out vaccinations, the slow pace of vaccine supply we are now seeing risks widening the gap between the world's vaccinated and the unvaccinated populations,'ť he said, charging that it's unfair that some wealthy nations 'œare looking to vaccinate their entire populations'ť while Africa continues to lag behind.
There are ongoing discussions between WHO, the global vaccine alliance GAVI and Indian authorities aimed at ensuring COVAX shipments continue to be prioritized, the official said.
Africa hopes to vaccinate 60% of its 1.3 billion people by mid-2022 in order to achieve herd immunity, when enough people are protected through infection or vaccination to make it difficult for a virus to continue to spread. That amounts to about 1.5 billion vaccine doses.
That target almost certainly will not be met without widespread use of the AstraZeneca vaccine, which many experts see as key to the global strategy to stamp out the coronavirus pandemic. The vaccine from the Anglo-Swedish drugmaker is cheaper and easier to store than many others. It will make up nearly all of the doses shipped in the first half of the year via COVAX.
Experts have warned that until vaccination rates are high the world over, the virus remains a threat everywhere.
'œWe are all in this together. This is a global pandemic, and we need to solve it through global vaccination, global public health methods," said Anthony Costello, a professor of global health and sustainable development at University College London.
Costello told the WHO briefing that while Africa, with its much younger population, is seeing lower death rates than other regions, "we must put pressure on wealthy countries to ensure that they offer the finance and the assistance to Africa to get the required number of vaccines.'ť
Africa has confirmed more than 4 million cases of COVID-19, including 110,000 deaths, according to the Africa CDC.
___
Follow AP's pandemic coverage at:
https://apnews.com/hub/coronavirus-pandemic
https://apnews.com/hub/coronavirus-vaccine
https://apnews.com/UnderstandingtheOutbreak
A frontline worker receives a shot of the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)
The Associated Press
A nurse, left, prepares a shot of AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, from a portable cold storage box, center, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)
The Associated Press
People wait in a queue to get a shot of the sinopharm coronavirus vaccination, at Wilkins Hospital in Harare, Wednesday, March, 24, 2021. Zimbabwe is rolling out its COVID-19 inoculation programme and in the first phase is targeting health care workers and the elderly. (AP Photo/Tsvangirayi Mukwazhi)
The Associated Press
People wait in a queue to get a shot of the sinopharm coronavirus vaccination at Wilkins Hospital in Harare, Wednesday, March, 24, 2021. Zimbabwe is rolling out its COVID-19 inoculation programme and in the first phase is targeting health care workers and the elderly. (AP Photo/Tsvangirayi Mukwazhi)
The Associated Press
Zimbabwean President Emmerson Mnangagwa, centre, receives his shot of the Chinese Sinovac COVID-19 vaccine in Victoria Falls, Wednesday March 24, 2021. Mnangagwa got his jab in the resort town of Victoria Falls, in a bid to promote tourism and launch the second phase of the countrys vaccination drive.(AP Photo/STR)
The Associated Press
People wait in a queue to get a shot of the sinopharm coronavirus vaccination at Wilkins Hospital in Harare, Wednesday, March, 24, 2021. Zimbabwe is rolling out its COVID-19 inoculation programme and in the first phase is targeting health care workers and the elderly. (AP Photo/Tsvangirayi Mukwazhi)
The Associated Press
A police officer has his blood pressure taken before receiving a shot of the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)
The Associated Press
A vial of the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, is removed from a portable cold storage box in preparation for a vaccination, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)
The Associated Press
A police officer has his blood pressure taken before receiving a shot of the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)
The Associated Press
A nurse holds a vial of the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India and provided through the global COVAX initiative, prior to vaccination in Machakos, Kenya, Wednesday, March 24, 2021. AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say. (AP Photo/Brian Inganga)
The Associated Press